Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4668862 | 0.83 | ABCC1 (0.42) | TSHRNPC1RAB9ACA1CA2 | |
| SCHEMBL4668960 | 0.81 | CXCR2 (0.38) | RAB9ACA1CA2CA9POLB | |
| SCHEMBL10883374 | 0.81 | APEX1 (0.49) | APEX1TSHRHTTNPC1RAB9A | |
| SCHEMBL4670142 | 0.81 | APEX1 (0.40) | APEX1TSHRHTTNPC1RAB9A | |
| SCHEMBL4667913 | 0.81 | MAPT (0.39) | CA1CA2ALDH1A1 | |
| SCHEMBL4669073 | 0.81 | APEX1 (0.45) | APEX1TSHRHTTCA1CA2 | |
| SCHEMBL4667381 | 0.80 | ALDH1A1 (0.44) | NPC1RAB9ACA1CA2CA12 | |
| SCHEMBL4669248 | 0.80 | ALDH1A1 (0.40) | NPC1RAB9ACA1CA2CA12 | |
| SCHEMBL7250153 | 0.79 | HPGD (0.42) | TSHRHTTNPC1RAB9AALDH1A1 | |
| SCHEMBL29227404 | 0.79 | HTT (0.50) | APEX1TSHRHTTCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1129689-B1 | Keratinous fiber dyeing composition comprising N-(2-hydroxybenzene)-carbamate or N-(2-hydroxybenzene)urea derivatives as coupling agents and process for dyeing | OREAL (FR) | 2008-07-09 | — | — | EP | claimed |
| US-6635091-B2 | Oxidation color dye and coupler | L'OREAL S. A. (FR) | 2003-10-21 | — | — | US | claimed |
| US-20020178512-A1 | Oxidation dyeing composition for keratinous fibres comprising a n-(2-hydrobenzene)-carbamate or a n-(2-hydroxy-benzene)-urea and a pyrazolopyrimine, dyeing methods | L'OREAL SA (FR) | 2002-12-05 | — | — | US | claimed |
| EP-1175198-A1 | OXIDATION DYEING COMPOSITION FOR KERATINOUS FIBRES COMPRISING A N-(2-HYDROBENZENE)-CARBAMATE OR A N-(2-HYDROXY-BENZENE)-UREA AND A PYRAZOLOPYRIMINE, DYEING METHODS | L'OREAL (FR) | 2002-01-30 | — | — | EP | claimed |
| US-20010034914-A1 | Compositions for the oxidation dyeing of keratinous fibers comprising at least one coupler, and dyeing methods | L'OREAL S.A. (FR) | 2001-11-01 | — | — | US | claimed |
| EP-1129689-A2 | Keratinous fiber dyeing composition comprising N-(2-hydroxybenzene)-carbamate or N-(2-hydroxybenzene)urea derivatives as coupling agents and process for dyeing | L'OREAL (FR) | 2001-09-05 | — | — | EP | claimed |
| WO-2001062220-A1 | OXIDATION DYEING COMPOSITION FOR KERATINOUS FIBRES COMPRISING A N-(2-HYDROBENZENE)-CARBAMATE OR A N-(2-HYDROXY-BENZENE)-UREA AND A PYRAZOLOPYRIMINE, DYEING METHODS | L'OREAL (FR) | 2001-08-30 | — | — | WO | claimed |
| EP-1129689-B1 | Keratinous fiber dyeing composition comprising N-(2-hydroxybenzene)-carbamate or N-(2-hydroxybenzene)urea derivatives as coupling agents and process for dyeing | OREAL (FR) | 2008-07-09 | — | — | EP | disclosed |
| US-6635091-B2 | Oxidation color dye and coupler | L'OREAL S. A. (FR) | 2003-10-21 | — | — | US | disclosed |
| US-20020178512-A1 | Oxidation dyeing composition for keratinous fibres comprising a n-(2-hydrobenzene)-carbamate or a n-(2-hydroxy-benzene)-urea and a pyrazolopyrimine, dyeing methods | L'OREAL SA (FR) | 2002-12-05 | — | — | US | disclosed |
| EP-1175198-A1 | OXIDATION DYEING COMPOSITION FOR KERATINOUS FIBRES COMPRISING A N-(2-HYDROBENZENE)-CARBAMATE OR A N-(2-HYDROXY-BENZENE)-UREA AND A PYRAZOLOPYRIMINE, DYEING METHODS | L'OREAL (FR) | 2002-01-30 | — | — | EP | disclosed |
| US-20010034914-A1 | Compositions for the oxidation dyeing of keratinous fibers comprising at least one coupler, and dyeing methods | L'OREAL S.A. (FR) | 2001-11-01 | — | — | US | disclosed |
| EP-1129689-A2 | Keratinous fiber dyeing composition comprising N-(2-hydroxybenzene)-carbamate or N-(2-hydroxybenzene)urea derivatives as coupling agents and process for dyeing | L'OREAL (FR) | 2001-09-05 | — | — | EP | disclosed |
| WO-2001062220-A1 | OXIDATION DYEING COMPOSITION FOR KERATINOUS FIBRES COMPRISING A N-(2-HYDROBENZENE)-CARBAMATE OR A N-(2-HYDROXY-BENZENE)-UREA AND A PYRAZOLOPYRIMINE, DYEING METHODS | L'OREAL (FR) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034914-A1 | Compositions for the oxidation dyeing of keratinous fibers comprising at least one coupler, and dyeing methods | KRT18, FH, FGB | APEX1 470/4885TSHR 4088/4885HTT 1274/4885 |
| US-20020178512-A1 | Oxidation dyeing composition for keratinous fibres comprising a n-(2-hydrobenzene)-carbamate or a n-(2-hydroxy-benzene)-urea and a pyrazolopyrimine, dyeing methods | FH, KRT18, CYB5R3 | APEX1 586/4885TSHR 4214/4885HTT 663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.